Drug Development in Asia: Scattering the Mist

Posted 23 February 2016 By Kwee-Tat Chew, MBA, BPharm, Rao Meenakshi, PhD, RAC

placeholder+image This article discusses misconceptions and their causes, surrounding drug development in Asia, and explains the regions current drug development landscape.

Share this article:

Categories: Biologics and biotechnology, Drugs, Clinical, Submission and registration, Features, Japan, China, Korea, Asean, MHLW, PMDA, CFDA, MFDS, ICH, APEC

Tags: Data exclusivity, tripartite cooperation on clinical research, Tripartite Working Group, TRIPS, ICH-E5, APEC, ASEAN, Biosimilars

Regulatory Exchange: Latest Updates From the Community